Edgewise Therapeutics Inc

EWTX is in a Stage 4 Decline with a decisive Support Failure pattern marking a breakdown. The medium-term bias is bearish, reinforced by downtrending EMAs and a failed rally into 9/21 EMA resistance. Short-term conditions have produced a bounce into the 9/21 EMA zone and rejection, offering an immediate sell opportunity. We recommend selling now on rallies into the 9/21 EMA resistance region.

• ↑$1.55B upfront from Servier acquisition funds cardiovascular R&D
• ↑EDG-7500 moved into Phase 3 after strong Phase 2 results
• ↓Lack of profitability shows struggles to generate efficient returns